Recurrent Breast Cancer

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (06-30-2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (06-22-2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (01-25-2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (10-26-2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (10-9-2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (10-1-2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (08-4-2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status,... Continue Reading

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (03-9-2015)

Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival and time to cancer... Continue Reading

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer (03-5-2015)

The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and progesterone receptor... Continue Reading

Breast Cancer Research: Have We Made Progress? (01-27-2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Next Page »